Literature DB >> 7247762

Loss of strength and functional decline in Duchenne's dystrophy.

K G Allsop, F A Ziter.   

Abstract

Clinical tests of strength and function were performed on 27 ambulatory patients with Duchenne's dystrophy every three months for 2 1/2 years. Linear decline of strength remains a fundamental characteristic of Duchenne's dystrophy. Although generally considered a homogeneous disease, our patients showed a broad spectrum of disability. Current tests of functional ability are poor measures of disease progression during most of the ambulatory period, since efficiency is maintained despite continuous decline in muscle strength. However, after this "latent" phase, failure of certain functions paralleled muscle deterioration closely, since task loss occurred within a narrow range of composite muscle strength. Finally, data on changes in body weight showed that most patients were excessively thin rather than obese. It is concluded that manual muscle strength testing remains the most valid method of monitoring disease progression and must be included in patient assessment.

Entities:  

Mesh:

Year:  1981        PMID: 7247762     DOI: 10.1001/archneur.1981.00510070040004

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  8 in total

Review 1.  Prevention and management of limb contractures in neuromuscular diseases.

Authors:  Andrew J Skalsky; Craig M McDonald
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-08       Impact factor: 1.784

2.  Short stature: a common feature in Duchenne muscular dystrophy.

Authors:  U Eiholzer; E Boltshauser; D Frey; L Molinari; M Zachmann
Journal:  Eur J Pediatr       Date:  1988-08       Impact factor: 3.183

3.  Clinical heterogeneity of duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up.

Authors:  Isabelle Desguerre; Christo Christov; Michele Mayer; Reinhard Zeller; Henri-Marc Becane; Sylvie Bastuji-Garin; France Leturcq; Catherine Chiron; Jamel Chelly; Romain K Gherardi
Journal:  PLoS One       Date:  2009-02-05       Impact factor: 3.240

4.  Growth hormone evaluation in Duchenne muscular dystrophy.

Authors:  L Merlini; C Granata; A Ballestrazzi; F Cornelio; P Tassoni; S Tugnoli; E Cacciari
Journal:  Ital J Neurol Sci       Date:  1988-10

5.  The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy.

Authors:  D M Bonifati; S F Witchel; M Ermani; E P Hoffman; C Angelini; E Pegoraro
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-10       Impact factor: 10.154

6.  β-Glucans as Dietary Supplement to Improve Locomotion and Mitochondrial Respiration in a Model of Duchenne Muscular Dystrophy.

Authors:  Letizia Brogi; Maria Marchese; Alessandro Cellerino; Rosario Licitra; Valentina Naef; Serena Mero; Carlo Bibbiani; Baldassare Fronte
Journal:  Nutrients       Date:  2021-05-12       Impact factor: 5.717

7.  The effects of electrical stimulation and exercise therapy in patients with limb girdle muscular dystrophy. A controlled clinical trial.

Authors:  Muhammed Kilinç; Sibel A Yildirim; Ersin Tan
Journal:  Neurosciences (Riyadh)       Date:  2015-07       Impact factor: 0.906

8.  Non-operative treatment for perforated gastro-duodenal peptic ulcer in Duchenne muscular dystrophy: a case report.

Authors:  Justus-Martijn Brinkman; Jorg R Oddens; Barend J Van Royen; Jan Wever; Jan G Olsman
Journal:  BMC Surg       Date:  2004-01-08       Impact factor: 2.102

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.